A Clinical Study to Explore the Safety, Efficacy, and Pharmacokinetics of CT0596 CAR-T Cell Injection in Patients With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs CT 0596 (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
- 20 Dec 2024 New trial record